|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
1,860,000,000 |
Market
Cap: |
17.65(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$9.2715 - $16.145 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Astellas Pharma is a pharmaceutical company. Co.'s main products include XTANDI, Betanis/Myrbetriq/BETMIGA, XOSPATA, Evrenzo and PADCEV. XTANDI is an androgen receptor signaling inhibitor indicated for the treatment of forms of advanced prostate cancer. Betanis/Myrbetriq/BETMIGA is for Overactive Bladder (OAB) treatment, a beta-3 adrenergic receptor agonist. XOSPATA is a FLT3 inhibitor for adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) with a FLT3 mutation-positive. PADCEV (enfortumab vedotin-ejfv), a treatment for adult patients with locally advanced or metastatic urothelial cancer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|